ReviewEuropean journal of clinical investigation2025
Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.
Review in European journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Blood-labyrinth barrier disruption associates with hypercholesterolemia-induced hearing loss.iScience · 2026Article
- Neuroimmune Regulation of Microvascular Inflammation: The Heart-Brain Axis, Mast Cells, and the Protective Role of Flavonoids-A Comprehensive Review.Biomedicines · 2026Review
- New frontiers in the treatment of hypercholesterolaemia: oral inhibition of PCSK9.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Assessment of N/L ratio and subclinical atherosclerosis in FH subjects with or without LDLR mutation.Journal of the Endocrine Society · 2026Article
- Association between the cumulative atherogenic index of plasma and cardiometabolic multimorbidity: the mediating effects of the TyG index and body mass index.Lipids in health and disease · 2026Article
- LDAR outperforms other albumin-derived indices in predicting 28-day ICU mortality in critically ill myocardial infarction patients: a two-cohort study.Frontiers in medicine · 2026Article
- Predictive Value of NLRP3 Inflammasome Activation for Unstable Plaques and Major Adverse Cardiovascular Events in Coronary Heart Disease.Journal of inflammation research · 2026Article
- Association between S100A12 and risk of peripheral arterial disease in patients with dyslipidemia: a cross-sectional study.BMC cardiovascular disorders · 2025Article
- The interleukin gene landscape: understanding its influence on inflammatory mechanisms in apical periodontitis.Molecular biology reports · 2025Review
- Chronic Inflammatory Diseases and Cardiovascular Risk: Current Insights and Future Strategies for Optimal Management.International journal of molecular sciences · 2025Review
- Emerging oral therapeutic strategies for inhibiting PCSK9.Atherosclerosis plus · 2025Review
- HDL-replacement therapy: From traditional to emerging clinical applications.Atherosclerosis plus · 2025Review
- Hypercholesterolemia and inflammation-Cooperative cardiovascular risk factors.European journal of clinical investigation · 2025Review
- From Cholesterol Metabolism to Comprehensive Lipid Management and Crosstalk of Inflammation: Expanding the Frontiers of Cardiovascular Prevention.Arquivos brasileiros de cardiologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMaintaining low concentrations of plasma low-density lipoprotein cholesterol (LDLc) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and delays the age at which mature atherosclerotic plaques develop. This substantially reduces the lifetime risk of atherosclerotic cardiovascular disease (ASCVD) events. In this context, plaque development and vulnerability result not only from lipid accumulation but also from inflammation.
resultsChanges in the composition of immune cells, including macrophages, dendritic cells, T cells, B cells, mast cells and neutrophils, along with altered cytokine and chemokine release, disrupt the equilibrium between inflammation and anti-inflammatory mechanisms at plaque sites. Considering that it is not a competition between LDLc and inflammation, but instead that they are partners in crime, the present narrative review aims to give an overview of the main inflammatory molecular pathways linked to raised LDLc concentrations and to describe the impact of lipid-lowering approaches on the inflammatory and lipid burden. Although remarkable changes in LDLc are driven by the most recent lipid lowering combinations, the relative reduction in plasma C-reactive protein appears to be independent of the magnitude of LDLc lowering.
conclusionIdentifying clinical biomarkers of inflammation (e.g. interleukin-6) and possible targets for therapy holds promise for monitoring and reducing the ASCVD burden in suitable patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.